Trevi Therapeutics Inc.
TRVI | NASDAQ
$15.17
+$0.28 (+1.88%)
Sep 22, 2026, 1:11 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 47K |
Gross Profit | n/a | n/a | n/a | n/a | n/a | -47K |
Operating Income | -49.33M | -51.52M | -33.92M | -29.91M | -32.48M | -32.49M |
Interest Income | 6.54M | 3.6M | 4.75M | 1.74M | 10K | 178K |
Pretax Income | -42.82M | -47.94M | -29.1M | -29.19M | -33.96M | -32.78M |
Net Income | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M | -32.76M |
Selling & General & Admin | 15.85M | 12.15M | 10.24M | 10.07M | 9.49M | 10.16M |
Research & Development | 33.48M | 39.38M | 23.68M | 19.83M | 22.98M | 22.33M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 49.33M | 51.52M | 33.92M | 29.91M | 32.48M | 32.49M |
Interest Expense | n/a | 4K | 391K | 780K | 1.2M | 456K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 49.33M | 51.52M | 33.92M | 29.91M | 32.48M | 32.49M |
Income Tax Expense | -64K | -30K | -32K | -36K | -21K | -18K |
Shares Outstanding (Basic) | 145.1M | 101.04M | 99.03M | 64.54M | 22.84M | 18.06M |
Shares Outstanding (Diluted) | 145.1M | 101.04M | 99.03M | 64.54M | 22.84M | 18.06M |
EPS (Basic) | -0.29 | -0.47 | -0.29 | -0.45 | -1.49 | -1.81 |
EPS (Diluted) | -0.29 | -0.47 | -0.29 | -0.45 | -1.49 | -1.81 |
EBITDA | -42.68M | -47.79M | -28.58M | -27.98M | -32.71M | -32.27M |
EBIT | -42.82M | -47.94M | -28.71M | -28.03M | -32.76M | -32.32M |
Depreciation & Amortization | 144K | 147K | 123K | 43K | 50K | 47K |
Add to Watchlist
Select watchlists to add or remove TRVI